Since these effects in the RAAS and TMPRSS2 may potentialize SARS-CoV-2 infectivity and increase risk of thromboembolic events, aromatase inhibitors should be discouraged as candidates for COVID-19. Here, TMPRSS2 is linked to COVID-19.